Vir Biotechnology, Inc. VIR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -720.8%+2,379pp | -699.2%+92.1pp | -3,253.6%-2,479pp | -3,191.7%— | -3,099.7%— | |
| Net margin | -676%+2,093pp | -638.9%+64.5pp | -2,963.5%-2,285pp | -2,895.9%— | -2,769%— | |
| EBITDA margin | -703%+2,335pp | -682.1%+89.5pp | -3,184.4%-2,430pp | -3,130.8%— | -3,037.8%— | |
| Free cash flow margin | -686.5%+1,337pp | -578.5%+32.8pp | -2,728.5%-2,126pp | -2,454.6%-1,873pp | -2,023.6%-1,045pp | |
| Returns | ||||||
| Return on equity | -47.7%-3.1pp | -45.7%-7.6pp | -49.1%-12.5pp | -46.2%— | -44.6%— | |
| Return on assets | -37.9%-0.7pp | -36.5%-5.0pp | -39.7%-9.6pp | -38.4%— | -37.2%— | |
| Return on invested capital | -67.6%-10.3pp | -61.8%-12.5pp | -60.7%-10.4pp | -61.4%— | -57.2%— | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 7.1×+0.3× | 5.5×-3.2× | 7.3×-1.7× | 7×-5.5× | 6.8×-6.1× | |
| Quick ratio | 7.1×+0.3× | 5.5×-3.2× | 7.3×-1.7× | 7×-5.5× | 6.8×-6.1× | |
| Cash ratio | 3.8×+1.2× | 2.6×-0.1× | 2.4×+0.1× | 2.9×-0.4× | 2.7×+0.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $5.52-27.4% | $5.52-34.6% | $5.73-36.9% | $6.84-35.0% | $7.59-33.6% | |
| Valuation | ||||||
| Market capitalization | $1.43B+61.1% | $838.92M-17.0% | $793.21M-22.3% | $728.51M-39.5% | $888.69M-35.2% | |
| Enterprise value | $1.24B+102% | $695.71M-11.9% | $714.13M-17.8% | $524.47M-47.6% | $616.79M-53.0% | |
| Price / sales | 21.9×-20.7× | 12.2×-1.4× | 47×+34.1× | 38.3×+23.1× | 42.6×+25.4× | |
| Price / book | 1.8×+0.9× | 1.1×+0.2× | 1×+0.2× | 0.8×-0.1× | 0.9×0.0× | |
| EV / sales | 19×-10.6× | 10.1×-0.5× | 42.4×+31.3× | 27.6×+14.9× | 29.6×+13.1× | |
| Free cash flow yield | -31.4%+16.1pp | -47.3%-2.4pp | -58%-11.6pp | -64%-25.9pp | -47.5%+9.3pp | |
| Earnings yield | -30.9%+34.1pp | -52.2%-0.6pp | -63%-10.7pp | -75.5%— | -65%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vir Biotechnology, Inc.'s profit margins?
- Vir Biotechnology, Inc. (VIR) runs a 96.1% gross margin and a -720.8% operating margin, with a -676.0% net margin.
- Where do Vir Biotechnology, Inc.'s ratios come from?
- Every ratio is computed from Vir Biotechnology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.